RxSight reports preliminary Q2 2025 financial results.

• RxSight faces a class action lawsuit for alleged securities fraud. • Investors who purchased RxSight securities during the Class Period must act by September 22, 2025. • The lawsuit concerns whether RxSight and certain officers and directors engaged in unlawful business practices. • A copy of the Complaint can be obtained at www.pomerantzlaw.com. • Preliminary second quarter 2025 financial results were reported on July 8, 2025.

Title: RxSight Faces Securities Fraud Class Action Lawsuit

RxSight, Inc. (NASDAQ: RXST), a commercial-stage medical technology company, is facing a class action lawsuit alleging securities fraud. The lawsuit, captioned Makaveev v. RxSight, Inc., No. 25-cv-01596, is pending in the U.S. District Court for the Central District of California [1]. The suit claims that RxSight made false and misleading statements about its financial performance between November 7, 2024 and July 8, 2025.

The complaint, filed on behalf of investors who purchased or acquired RxSight securities during this period, alleges that the company failed to disclose significant "adoption challenges" and structural issues resulting in declines in sales and utilization. Additionally, it is claimed that RxSight overstated the demand for its products and failed to meet its previously issued financial guidance for fiscal year 2025 [1].

On July 8, 2025, RxSight reported preliminary second quarter of 2025 financial results, revealing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue. The company also lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint. This news led to a significant decline in the price of RxSight stock, falling nearly 38% [2].

Investors who suffered substantial losses in their investments in RxSight are eligible to participate in the lawsuit. The Private Securities Litigation Reform Act of 1995 allows any investor who purchased or acquired RxSight securities during the class period to seek appointment as lead plaintiff in the lawsuit. The deadline to file a lead plaintiff motion is September 22, 2025 [3].

For more information or to discuss legal rights and options, investors are encouraged to contact Bernstein Liebhard LLP, Robbins Geller Rudman & Dowd LLP, or Glancy Prongay & Murray LLP, as indicated in the respective press releases [1, 2, 3].

References:
[1] https://www.ainvest.com/news/rxsight-investors-alert-deadline-securities-fraud-lawsuit-nears-2508/
[2] https://www.globenewswire.com/news-release/2025/08/03/3126226/0/en/RXST-LEGAL-ALERT-Lose-Money-on-Your-RxSight-Inc-Investment-Contact-BFA-Law-by-September-22-Class-Action-Deadline-NASDAQ-RXST.html
[3] https://www.globenewswire.com/news-release/2025/08/07/3129543/0/en/RXST-INVESTOR-ALERT-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-RxSight-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Securities-Class-Action-Lawsuit.html